Who Is Buying Thermo Fisher Scientific? Hedge Fund Activity in 2026

Thermo Fisher Scientific is the world's largest life sciences tools company — the "picks and shovels" play for biotech, pharma, and academic research. At around $491.66 per share, TMO is a premium-valued compounder that has delivered exceptional long-term returns through a combination of organic growth, disciplined M&A, and operational excellence. Whether scientists are developing gene therapies, testing water quality, or running clinical trials, Thermo Fisher's instruments and consumables are essential. The company serves over 400,000 customers globally and has built one of the widest competitive moats in the healthcare industry.

The latest 13F filings reveal an overwhelmingly bullish institutional picture, highlighted by three major hedge funds opening brand-new positions simultaneously.

Thermo Fisher Scientific Institutional Snapshot

An 8-to-4 buy-sell ratio with 6 holding creates a solidly bullish institutional profile. The quality and conviction of the buyers make the signal even stronger.

Who's Buying Thermo Fisher?

The buying side features a powerful combination of passive giants, active fundamental managers, and systematic hedge funds:

Vanguard holds $16.8 billion and increased, anchoring the institutional ownership base. Fidelity at $4.8 billion (increased) and State Street at $8.2 billion (increased) complete the top three — all adding to already massive positions.

Citadel increased to $339.3 million, a substantial bet from the multi-strategy powerhouse. Citadel's addition suggests both systematic and fundamental conviction in TMO's setup.

When the three largest institutional managers all increase simultaneously, it creates powerful upward pressure on the stock through index rebalancing and active accumulation. Combined, these three hold over $29 billion in TMO — a massive institutional base that provides stability and support.

The most exciting buying activity, however, comes from the new entrants (covered below in Notable Moves).

Who's Selling Thermo Fisher?

The selling side is modest in both number and conviction:

Appaloosa Management decreased to $71.1 million — a trim rather than an exit, suggesting David Tepper's fund is managing position size rather than changing its fundamental view.

Baker Bros Advisors reduced to $44.5 million. As a healthcare-focused fund, Baker Bros' reduction is worth noting, though the relatively small position size suggests TMO was never a core conviction holding.

Millennium Management trimmed to $25.7 million, and D.E. Shaw decreased to $23.4 million. Both trims are modest and likely reflect portfolio-level rebalancing rather than bearish conviction.

Notably, no fund completely exited its Thermo Fisher position — a bullish signal in itself.

Notable Moves

The filing period's headline story for Thermo Fisher is the simultaneous opening of three new positions by major hedge funds:

Viking Global initiated a brand-new position worth $389.8 million. This is a significant commitment from Andreas Halvorsen's fund, which is known for concentrated, high-conviction bets in quality companies. Viking doesn't dabble — a nearly $400 million opening position signals deep fundamental work and conviction in TMO's long-term trajectory.

Two Sigma opened a new position, bringing quantitative validation to the fundamental thesis. When systematic models identify a stock as attractive enough to initiate a new holding, it suggests favorable statistical properties in the data.

Bridgewater also opened a new position, adding macro-informed systematic buying to the mix. Ray Dalio's fund establishing a position in a life sciences tools company may reflect broader portfolio construction views about the healthcare and technology convergence.

Three sophisticated funds independently deciding to initiate new TMO positions in the same quarter is a powerful convergence signal. This doesn't happen by accident — it suggests something in Thermo Fisher's setup has reached an inflection point that multiple investment approaches are detecting simultaneously.

What This Signals

The institutional picture for Thermo Fisher Scientific is strongly bullish across the board:

New money is flowing in. Three new positions totaling over $389.8 million (Viking alone) plus two more from Two Sigma and Bridgewater represent fresh institutional capital finding its way into TMO. This is qualitatively different from existing holders adding — it means new investors are clearing their research bars and deciding TMO deserves capital allocation.

No one is leaving. Zero complete exits among 18 tracked funds is a powerful retention signal. Even the funds trimming are maintaining positions, suggesting they still see long-term value even if they're managing risk at the margin.

The quality premium is justified. Thermo Fisher trades at a premium valuation, but the institutional buying confirms that sophisticated investors are willing to pay up for quality. TMO's competitive moat — installed base of instruments generating recurring consumables revenue — is exactly the kind of business model that compounds value over time.

Life sciences tools are back in favor. After a post-pandemic hangover where destocking and reduced biotech funding pressured the sector, the institutional buying in TMO suggests smart money believes the trough is behind us. Viking's massive new position is a particularly strong signal that the sector setup has improved.

The M&A optionality adds value. Thermo Fisher has a proven track record of acquiring and integrating complementary businesses — a capability that creates ongoing optionality for growth acceleration. Institutional buyers may be pricing in the potential for additional value-creating deals, given TMO's strong balance sheet and management's deal-making expertise.

The recurring revenue model creates predictability. A significant portion of Thermo Fisher's revenue comes from consumables and services tied to its installed base of instruments. This razor-and-blade business model generates highly predictable cash flows that institutional investors prize — especially in uncertain macro environments where revenue visibility becomes a competitive advantage.

Biotech funding recovery is a tailwind. After a period of constrained biotech funding that reduced demand for life sciences tools, the funding environment is showing signs of recovery. Increased NIH budgets, recovering biotech IPO activity, and growing pharma R&D spending all benefit Thermo Fisher's end markets — a dynamic that likely contributed to Viking, Two Sigma, and Bridgewater's decision to initiate positions.

For investors, Thermo Fisher's 13F data presents a clear institutional consensus: this is a quality compounder that smart money wants to own. The combination of existing holder accumulation and significant new position openings makes TMO one of the most institutionally supported stocks in the healthcare tools space.

---

Track TMO institutional moves in real-time with Freenance Smart Money — we track 35 funds with $21.4T total AUM across 77,111 positions. See who's buying and selling at app.freenance.io/smart-money/ticker/TMO.

Related Articles

• Who Is Buying NVIDIA? Hedge Fund Activity in 2026
• Who Is Buying Apple? Hedge Fund Activity in 2026
• Who Is Buying Tesla? Hedge Fund Activity in 2026

FAQ

Why is the life-sciences tools sector a "picks and shovels" play?

Thermo Fisher sells instruments, consumables, and services that virtually every biotech, pharma, academic, and clinical research lab relies on. That positions the company as a beneficiary of overall research and diagnostic activity, regardless of which specific drug or therapy succeeds. Institutional funds often favor this exposure because it captures sector growth without single-asset clinical risk.

How does the biotech funding cycle affect Thermo Fisher's demand?

When biotech IPO windows are open and venture funding is plentiful, early-stage labs ramp instrument and consumable purchases, which lifts Thermo Fisher's bookings. During capital-constrained periods, smaller customers stretch capex and defer instrument upgrades. Funds watch biotech XBI performance, NIH budget appropriations, and pharma R&D spend as leading indicators for TMO's end markets.

What role does the installed base play in the TMO investment case?

Thermo Fisher's installed base of analyzers, mass spectrometers, and lab instruments generates recurring consumables and service revenue over multi-year lifecycles. This razor-and-blade dynamic creates predictable cash flows that compound as the installed base grows. Institutional models typically value this recurring stream at a premium to one-time hardware revenue.

How does M&A factor into Thermo Fisher's growth profile?

TMO has a long track record of acquiring complementary businesses — diagnostics, bioproduction, lab services — and integrating them into its commercial engine. The cadence of deals provides optionality on top of organic growth and supports cross-selling into the installed base. Funds price in management's deal-making discipline alongside the underlying market growth rate.

What macro factors most influence TMO's end-market demand?

Pharma R&D budgets, NIH and global research funding, biotech capital availability, and clinical trial activity all shape demand. Currency moves matter as well, given Thermo Fisher's global revenue footprint. Institutional buyers triangulate these inputs to gauge whether the life-sciences capex cycle is in early recovery, mid-cycle, or late-cycle territory.